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Edited by Jesus AvilaAbstract Intracellular phosphorylation of dCK on Ser-74 re-
sults in increased nucleoside kinase activity. We mimicked this
phosphorylation by a Ser-74-Glu mutation in bacterially pro-
duced dCK and investigated kinetic parameters using various
nucleoside substrates. The S74E mutation increases the kcat val-
ues 11-fold for dC, and 3-fold for the anti-cancer analogues
dFdC and AraC. In contrast, the rate is decreased for the purine
substrates. In HEK293 cells, we found that by comparing tran-
siently transfected dCK(S74E)-GFP and wild-type dCK-GFP,
mimicking the phosphorylation of Ser-74 has no eﬀect on cellular
localisation. We note that phosphorylation may represent a
mechanism to enhance the catalytic activity of the relatively slow
dCK enzyme.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mammalian cells have four nucleoside kinases, thymidine
kinases (TK1 and TK2), deoxyguanosine kinase (dGK) and
deoxycytidine kinase (dCK), which partake in the ﬁrst phos-
phorylation step of the nucleotide salvage-pathway providing
resting cells with deoxynucleotides for mitochondrial DNA
synthesis and nuclear DNA repair [1–3]. Of these dCK has
the broadest substrate speciﬁcity phosphorylating the natural
deoxynucleosides, deoxyadenosine (dA), deoxycytidine (dC)
and deoxyguanosine (dG) [4]. Additionally, dCK phosphory-
lates a number of anti-viral and anti-cancer nucleoside ana-
logue prodrugs. Chemotherapy agents such as the cytidine
analogues Gemcitabine (dFdC) and Cytarabine (Ara-C), the
adenosine analogue Cladribine (CldA) [5] and anti-viral cyti-
dine analogues such as 3TC and ddC used to treat HIV infec-
tion [5,6], are converted by dCK in the ﬁrst step of intracellular
activation from their pharmacologically inactive form (pro-
drug) to their 5 0-phosphorylated species. Deﬁciencies in dCK
expression, or loss of dCK activity, are common factors that*Corresponding author. Fax: +49 551 2011074.
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ously shown that drug sensitivity can be restored and cellular
toxicity enhanced by increasing dCK activity through gene
transfer [7].
Until recently, the intracellular control mechanisms of dCK
activity were largely unknown. It has now been shown that
phosphorylation and dephosphorylation of dCK is important
in the regulation of dCK activity [8]. A total of four potential
in vivo phosphorylation sites were identiﬁed: Thr-3, Ser-11,
Ser-15 and Ser-74. Following mutational analyses of these four
sites, the Ser-74 residue, which lies in the surface-exposed in-
sert region of dCK [9], was shown to be the only phosphoryla-
tion site that inﬂuences intracellular activity. The authors
developed a phospho-Ser74 antibody raised to the phospho-
peptide (EELTMpSQKNGG) which comprises amino acids
69–79 of dCK. Using this antibody, a direct correlation be-
tween an elevated phosphorylation state of Ser-74 and in-
creased dCK activity was shown in both dCK overexpressed
in HEK 293 cells and endogenous dCK expressed in human
leukemic lymphocytes [8,10]. Although phosphorylation of
dCK appears to be an important post-translation regulatory
mechanism, the protein kinase which phosphorylates dCK
has yet to be identiﬁed by a biochemical approach. However,
a recent elegant proteomic study, which aimed to analyse pro-
teins phosphorylated on speciﬁc consensus sequences following
cellular DNA damage, may aid in identifying the kinase
responsible for the phosphorylation of Ser-74 on dCK [11].
The authors selected to identify proteins phosphorylated on
Ser-Gln (SQ) or Thr-Gln (TQ) motifs following the induction
of cellular DNA damage by ionizing radiation. Both SQ and
TQ motifs are substrates for ATM (ataxia telangiectasia mu-
tated) and ATR (ATM and Rad3 related) kinases which are
rapidly initiated when double-strand breaks in chromosomal
DNA arise in a cell. This study showed that when cells are sub-
jected to ionizing radiation human dCK is phosphorylated on
Ser-74 and this phosphorylation is ATM-dependant.
As dCK activity plays a critical role in the sensitivity to
nucleoside analogue prodrugs, in this study we mimicked
phosphorylation of Ser-74 on dCK by serine-to-glutamic
acid (S74E) or serine-to-aspartic acid (S74D) mutations and
analysed the eﬀects on enzymatic activity to both dFdC
and Ara-C, and to the natural nucleoside substrates dC, dG
and dA. Furthermore, to study the inﬂuence of side-chain
length and charge on Ser-74, enzymatic activities of dCK with
serine-to-glutamine (S74Q) and serine-to-alanine (S74A)
mutations were analysed. We also investigated the potential
inﬂuence of phosphorylation on cellular localisation of over-
expressed dCK.blished by Elsevier B.V. All rights reserved.
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2.1. Plasmid construction and site-directed mutagenesis
The human dCK Ser-74 mutants were constructed using the PCR-
fusion method and wild-type human dCK cDNA as the template [9].
The PCR products were subcloned via the 5 0-Nde I/3 0-Bam HI sites
into the pET14b vector (Novagen) providing a His6 tag at the N-termi-
nus. Wild-type dCK, and mutants dCK(S74E) and dCK(S74A) were
subcloned into mammalian green ﬂuorescent protein (GFP) expression
vector pEGFP-C1 (Clontech) via Nde I/Sal I sites. The N-terminal nu-
clear import signal of dCK WT and dCK (S74E) was abolished by a
double mutation (K6N and R7G) in the bipartite nuclear import signal
region (residues: 6–18) by PCR mutagenesis [12] and subcloned into
the pEGFP-C1 vector. All plasmid DNA was puriﬁed using a Nucleo-
Bond kit (Macherey-Nagel) according to the manufacturers instruc-
tions.2.2. Protein expression and puriﬁcation
BL21 (DE3) Escherichia coli was transformed with the dCK con-
structs in the pET14b vector, grown in 2YT media and induced with
0.1 mM IPTG over 4 h at 37 C [9]. Cells were harvested and the pellet
lysed by sonication. Lysates were cleared by centrifugation at
10000 · g for 30 min at 4 C and subjected to batch puriﬁcation with
Protino Ni-TED (Macherey-Nagel) following the suppliers protocol.
After elution with imidazole, the protein samples were aliquoted, snap-
frozen and stored at 80 C. Samples of puriﬁed enzyme were pre-
pared in Laemmli buﬀer, heated at 95 C and analysed on a 10%
SDS–PAGE gel.2.3. Kinetic assay
The activities of the dCK WT and dCK Ser-74 mutants were deter-
mined using an NADH-dependent enzyme-coupled assay [13] and a
Uvikon 943 spectrophotometer. All measurements were done at
25 C in a buﬀer containing 100 mM Tris, pH 7.5, 100 mM KCl,
10 mMMgCl2 and 2 mMATP. For kcat measurements, the nucleosides
dC, dA, dG and nucleoside analogues Gemcitabine (dFdC) or AraC
were used at saturating concentrations. For Km measurements, varying
ranges of nucleoside concentrations were used with, all other assaying
conditions kept constant: dC (0.01–1 mM), dA (0.05–4 mM), dG
(0.05–1 mM), dFdC (0.005–1 mM) or AraC (0.05–1 mM). Enzyme
concentrations varied between 0.3 and 1.6 lM depending on the nucleo-
side analog to be measured. Kinetic experiments carried out at 37 C
yielded kcat ratios for the S74E mutant and the wild-type enzyme that
were very similar to those obtained at 25 C (data not shown).
2.4. Cell culture, transient transfection and confocal laser-scanning
microscopy
Human embryonic kidney (HEK293) cells were maintained at 37 C
in an atmosphere of 5% CO2/95% humidity in complete Dulbeccos
Modiﬁed Eagle Medium (DMEM) supplemented with 0.1% penicil-
lin/streptomycin (10000 U/ml), L-glutamine (2 mM) and 10% fetal calf
serum. Transfection of HEK293 cells was done using Lipofectamine
2000 (Invitrogen) according to the manufacturers protocol. Transfec-
ted cells were seeded onto 12 mm glass cover-slips 1 day prior to ﬁxa-
tion. The cover-slips were washed with ice-cold HEPES-buﬀered saline
(HBS) and cells ﬁxed in 3.5% paraformaldehyde (PFA) for 5 min at
4 C and for 10 min at room temperature. The cover-slips were washed
three times with HBS and subjected further to ﬁxation and permeabil-
isation steps with methanol for 6 min at 20 C, washed once with
HBS and mounted in Mowiol [14]. Images of transfected cells were
taken using a Leica TCS SP5 confocal microscope.3. Results and discussion
Human dCK is a homodimeric protein of a calculated sub-
unit mass of 30.5 kDa (260 amino acids) [15]. The 3D structure
of human dCK (at 1.6 A˚ resolution) bound to ADP and to its
natural nucleoside substrate dC, or to the nucleoside analogues
Ara-C and dFdC, has been solved by Sabini et al. [9]. This
structure reveals that the putative Ser-74 phosphorylation siteof dCK lies in a surface-exposed insert region which would be
easily accessible to cellular protein kinases (Fig. 1A). In fact, in
several other crystal structures of dCK the entire insert region
could not be modeled, indicating the high ﬂexibility of this re-
gion. Furthermore, it has been postulated that phosphoryla-
tion of dCK and the resultant increase in activity is due to a
conformational change of the enzyme [16,17]. The exact nature
of this conformational change is unknown. We did not study
the role of three N-terminally located, minor phosphorylation
sites (Thr-3, Ser-11, Ser-15) that were identiﬁed previously and
were shown to have no eﬀect on dCK activity [8]. Since the N-
terminal region containing these residues is not conserved
among diﬀerent species [8] and could not be seen in our crystal
structure [9] we omit it from Fig. 1A.
Upon SDS–PAGE analysis, decreased electrophoretic
mobilities (band-shifts) have been reported for many proteins
and kinases upon phosphorylation [18,19]. In these cases,
decreases in electrophoretic mobility were correlated to an
elevation of the phosphorylation status of the protein and to
a concomitant increase in its catalytic activity. Such band-
shifts have also been previously shown for phosphorylated
and activated dCK [8]. We observed, following the separation
by SDS–PAGE of the various N-terminally His-tagged dCK
mutants Ser-74-Glu (S74E), Ser-74-Asp (S74D), Ser-74-Ala
(S74A) and Ser-74-Gln (S74Q), that the phospho-mimicking
S74E and S74D mutant enzymes have a slightly decreased elec-
trophoretic mobility (Fig. 1B). These observed properties
indicated that both our E. coli produced S74E and S74D
mutants of dCK are akin to the Ser-74 phosphorylation of
dCK in intact cells.
Next, we set out to investigate the eﬀect of mimicking the
phosphorylation of Ser-74 on the enzyme kinetics of recombi-
nant dCK using diﬀerent natural deoxynucleoside substrates
and nucleoside analogues. Here, we found that the most
marked changes in kcat occurred with the S74E variant. Com-
pared to WT, the S74E mutation resulted in an 11-fold in-
crease in kcat for dC, and 3-fold increase for the cytidine
analogues dFdC and Ara-C (Table 1a). No signiﬁcant change
was observed for the natural substrate dA, although the kcat
for the purine substrate dG decreased 2-fold. As with S74E,
the S74D mutation can potentially mimic the charged phos-
phoserine. However, the increase in rate was not as dramatic
with the S74D mutation for dC (4-fold), dFdC (2-fold) and
Ara-C (2-fold) (Table 1a). The S74Q mutation, generated in
order to observe the sole eﬀect of side-chain length, did not re-
sult in a signiﬁcant change in kcat for any of the substrates. The
S74A mutation also revealed no signiﬁcant changes in kcat for
any of the substrates (Table 1a). Finally, as the S74E mutation
resulted in an increased rate for dC and the dC analogues
dFdC and AraC, we determined the Km values and calculated
the kcat/KM ratios for the three physiological substrates and for
the two nucleoside analogues (Table 1b). The KM for dC and
Ara-C increased 4-fold for dCK-S74E variant compared to
dCK-WT. Thus, the speciﬁcity constant, as given by the kcat/
KM ratio, remains nearly unchanged in the case of AraC and
dFdC and increases about 2-fold for deoxycytidine. In con-
trast, it drops about 5-fold in the case of dA and dG, leading
to a considerably lower activity of the S74E variant on purine
substrates. It is important to realize that the improved kcat is
the overriding parameter that determines catalytic eﬀectiveness





WT S74E Ratio S74E/WT S74D S74Q S74A
(a) Catalytic activities of wild-type dCK and dCK phosphorylation site Ser-74 dCK mutants
dC 0.04 ± 0.005 0.45 ± 0.03 11.25 0.16 ± 0.003 0.04 ± 0.03 0.04 ± 0.003
dA 0.77 ± 0.07 0.69 ± 0.04 0.90 1.00 ± 0.07 0.90 ± 0.08 1.12 ± 0.10
dG 0.73 ± 0.05 0.36 ± 0.01 0.49 0.57 ± 0.05 0.65 ± 0.03 0.68 ± 0.04
dFdC 0.44 ± 0.03 1.21 ± 0.05 2.75 0.90 ± 0.02 0.45 ± 0.06 0.50 ± 0.03
AraC 0.32 ± 0.02 1.06 ± 0.04 3.31 0.57 ± 0.02 0.30 ± 0.08 0.33 ± 0.05
KM (lM) kcat/KM (M
1 s1)
WT S74E WT S74E
(b) Steady-state kinetic parameters KM and kcat/KM of dCK WT and dCK(S74E)
dC 1.7 ± 0.2 8.9 ± 0.3 23.1 · 103 50.6 · 103
dA 116.9 ± 11.5 517.9 ± 92.7 6.6 · 103 1.3 · 103
dG 245.8 ± 18.8 601.8 ± 80.2 2.9 · 103 0.6 · 103
dFdC 6.2 ± 1.3 15.0 ± 3.1 71.0 · 103 80.7 · 103
AraC 5.9 ± 1.5 24.1 ± 12.1 54.2 · 103 44.0 · 103
All kinetic measurements were performed at 25 C with 2 mM ATP as the phosphoryl donor and, as indicated, with diﬀerent nucleoside substrates.
Calculated kcat values include standard error (n = 4).
KM values were determined with constant 2 mM ATP and varying concentrations of substrates. All measurements were performed at 25 C. The KM
values are an average of at least three experiments and were calculated using Origin (Hyperbolic function). The kcat values from Table 1a were used to






















Fig. 1. (A) Ribbon diagram of a dCKmonomer highlighting the Ser-74 phosphorylation site in the insert region accessible to cellular protein kinases.
(B) Coomassie blue-stained SDS–PAGE gel showing the reduced mobility of the dCK(S74E) and dCK(S74D) mutant proteins mimicking S74
phosphorylation.
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compare to activity measurements done in mammalian cells?
Smal et al. [8] expressed dCK in HEK 293T cells and observed
that the dCK activity in cell lysates (measured with ATP and
dC as substrates) decreases by approximately a factor of 6
after phosphatase treatment. In contrast, speciﬁc enzymatic
activity as determined in lysates of cells expressing wild-type
dCK or dCK-S74E increased 1.5–2-fold in the mutant enzyme,
whereas the S74A mutant showed a 6–8-fold lower activity
than wild-type [8]. The interpretation here is that in these
experiments wild-type dCK represents a mixture of phosphor-
ylated and unphosphorylated enzyme, S74E the fully phos-
phorylated form, and the S74A version completely
unphosphorylated dCK. Taken together, the diﬀerence in
activity of the totally unphosphorylated enzyme and the phos-
phorylation mimic amounts to a factor of 10–12 in the HEK293T cellular system. This compares remarkably well to our
data obtained on bacterially produced wild-type and dCK-
S74E showing a ratio of 11 for the ATP/dC substrate pair.
As the intracellular phosphorylation of some proteins can
result in their subcellular re-localisation, we analysed this issue
by transiently transfecting both wild-type dCK and the
dCK(S74E) phosphorylation mutant fused to GFP [designated
dCK WT-GFP and dCK(S74E)-GFP, respectively] into
HEK293 cells (Fig. 2). Speciﬁc activity of the bacterially over-
produced and puriﬁed dCK-GFP proteins was about half of
that of the unfused species (unpublished data). Both dCK
WT-GFP and dCK(S74E)-GFP were found mainly in the nu-
cleus in contrast to the GFP only control, which was observed
throughout the cell. In order to rule out that the phosphoryla-
tion of Ser-74 inﬂuences localisation, we overexpressed
dCK(S74A)-GFP in HEK293 cells. The transiently transfected
Fig. 2. Comparison of the intracellular localisation of transiently expressed dCK WT, dCK(S74E), dCK(S74A), and nuclear import signal mutants
of dCK WT and dCK(S74E). HEK293 cells were transfected with the indicated N-terminal green ﬂuorescent protein (GFP)-fused dCK constructs;
dCK WT-GFP, dCK(S74E)-GFP, dCK(S74A)-GFP and dCK WT(DNLS)-GFP or dCKS74E(DNLS)-GFP where the nuclear import signal (NLS)
has been abolished. Empty pEGFP-C1 vector was used as the GFP control.
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(Fig. 2). Previously, it had been reported that endogenous
dCK is in fact cytosolic [20] and is only nuclear following over-
expression, and this was independent of the absence [20] or
presence [21] of C-terminally fused GFP. This nuclear redistri-
bution of overexpressed dCK was attributed to a nuclear local-
isation signal (NLS) found in the extreme N-terminal region of
dCK [20]. Furthermore, it was postulated that a binding part-
ner exists which keeps endogenous dCK in the cytosol whereas
overexpressed dCK is observed also in the nucleus due to an
imbalance of the binding partner/dCK ratio. Therefore, we
created further mutants dCK WT(DNLS)-GFP and dCK
S74E(DNLS)-GFP to abolish the nuclear localisation due to
the NLS. Our rationale was to observe whether mimicking
Ser-74 phosphorylation would have any eﬀect on cytosolic
overexpressed dCK-GFP as opposed to the normally nuclear
overexpressed dCK (Fig. 2). We found that both dCK
WT(DNLS)-GFP and dCK S74E(DNLS)-GFP were distrib-
uted uniformly in the cytosol. Thus, we conclude that there
is no eﬀect on the localization of dCK upon phosphorylation
of S74.
In summary, the data from our biochemical analysis of the
phosphorylation mimic dCK(S74E) suggest that the enzymes
catalytic activity can be upregulated about 10-fold, and ren-
dered more selective for dC substrates through phosphoryla-
tion of a single site. Since expression of the mammalian dCK
gene, in contrast to TK1 which shows highest level during
the S-phase, does not ﬂuctuate during the cell cycle, this
post-translational modiﬁcation may be considered as a mech-
anism for modulating its intracellular activity. Moreover,
enhancement of the ﬁrst, and often critical, phosphorylation
step in the activation pathway of deoxycytidine analog pro-
drugs protects them from rapid deamination, and, thus, deac-tivation. We are presently studying the structural consequences
of phosphorylation and its impact on protein stability and
interaction with potential binding partners, as well as cellular
eﬀects resulting from overexpression of dCK variants in hu-
man cells and treating them with nucleoside analogues.
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